Cantor Fitzgerald Investment Advisors’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Cantor Fitzgerald Investment Advisors’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$728K	Hold	74,000	–	–	0.03%	227
2021 Q4	$722K	Buy	+74,000	New	+$725K	0.04%	227

Other funds holding EUCR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

ECU

Eisler Capital (UK) London, United Kingdom $21.7B AUM 0.34% 1-Year Est. Return

Cantor Fitzgerald Investment Advisors's EUCR Position: Q1 2022 in Review

Cantor Fitzgerald Investment Advisors held its Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) position steady in Q1 2022 at 74,000 shares worth $728K. The position accounts for 0.03% of the portfolio, ranked #227.

Cantor Fitzgerald Investment Advisors first reported a position in EUCR in Q4 2021 and has held it in 2 quarters since. 39 funds tracked by Wall St. Rank hold EUCR as of Q1 2022.

Cantor Fitzgerald Investment Advisors held 74,000 shares of Eucrates Biomedical Acquisition Corp. Ordinary Shares worth $728K as of Q1 2022.
Cantor Fitzgerald Investment Advisors left its Eucrates Biomedical Acquisition Corp. Ordinary Shares share count unchanged in Q1 2022.
Eucrates Biomedical Acquisition Corp. Ordinary Shares made up 0.03% of Cantor Fitzgerald Investment Advisors's portfolio in Q1 2022, its #227 holding.
Cantor Fitzgerald Investment Advisors first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2021 and has held it in 2 quarters since.
39 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q1 2022.

Based on Cantor Fitzgerald Investment Advisors's 13F filing for Q1 2022, filed 13 Apr 2022.